Enrico Heffler
Enrico Heffler is an expert in Immunology at IRCCS Humanitas Research Hospital (Italy). As of October 2026, ScienceLeadR ranks Enrico Heffler in the top 1% of experts worldwide for Rhinosinusitis, Sinusitis and Nose Diseases. Enrico Heffler has authored 437 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 7 of them ongoing. SLR score: 1,478 (community average: 125). How the SLR is computed.
LeadR Profile
Immunology
Subspecialties: Pulmonology - Public Health - Otolaryngology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 437
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical Evaluation of Allergen Immunotherapy for Allergic Asthma. PMID 42936187 — allergens, immunotherapy, therapeutics, asthma | Biologics | 2026 | 0 |
| Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study. PMID 42936732 — registries, comorbidity, documentation, physicians, prevalence, multimorbidity, asthma, steroids, education, gastroesophageal reflux | J Asthma Allergy | 2026 | 0 |
| Innovative positioning of respiratory allergen immunotherapy: a focus on precision medicine. PMID 42751853 — rhinitis, allergic, hypersensitivity, allergens, immunotherapy, precision medicine, therapeutics, asthma, biological therapy, allergy | Expert Opin Biol Ther | 2026 | 0 |
| Emerging therapeutic strategies and clinical trials in severe asthma management: current evidence and future directions. PMID 42872730 — alarmins, biomarkers, precision medicine, therapeutics, asthma | Expert Opin Biol Ther | 2026 | 0 |
| Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP. PMID 42773700 — smokers, critical care, smoke, therapeutics, asthma, biological therapy, smoking | Am J Respir Crit Care Med | 2026 | 1 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ CSU1) 2024-513210-36-00 — histamine antagonists, safety, urticaria, therapeutics | Phase 3 | Active not recruiting | 2025 |
| A Study to Learn About the Study Medicine Called PF 07275315 in People With Moderate to Severe Asthma 2024-517866-40-00 — safety, asthma | Phase 2 | Recruiting | 2025 |
| A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab NCT06706817 — injections, polyps, signs and symptoms, therapeutics, nasal polyps, injections, subcutaneous, rhinosinusitis | Phase 3 | Active not recruiting | 2024 |
| Italian Registry of Allergen ImmunoTherapy NCT06499480 — registries, respiration disorders, respiratory tract diseases, respiration, hypersensitivity, allergens, immunotherapy | N/A | Recruiting | 2024 |
| Setting a PERSONalized Outcome in ASthma the PERSONAS Study A Patient Driven Outcome (PDO) Study NCT06320119 — therapeutics, asthma | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map